Challenge of rhesus monkeys with SIV after immunization with a combination regimen.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Challenge of rhesus monkeys with SIV after immunization with a combination regimen.

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 63. Unique Identifier : AIDSLINE PRIM11/94191659
Schlienger K; Mancini M; Riviere Y; Tiollais P; Michel ML; Unite de Recombinaison et Expression Genetique, Institut; Pasteur, Paris, France.

Abstract: We recently reported that recombinant Hepatitis B surface antigen (HBsAg) particles presenting the HIV-1BRU envelope principal neutralizing determinant on their surface (V3/HBsAg) allowed us to generate proliferative T-cell responses, cellular cytotoxicity and neutralizing antibodies in immunized rhesus monkeys. To evaluate the protective immunity against homologous challenge that may be elicited by the hybrid particles in the SIV/macaque model, we presented the second variable domain (V2) of SIVMAC251 gp140 on HBsAg particles. This domain is involved in generation of cell-free virus neutralizing antibodies. We used a combination immunization regimen that included a live recombinant vaccinia virus for priming and the hybrid V2/HBsAg particle for boosting in order to maximize both the cellular and the humoral responses. Four rhesus monkeys received 2 intradermal injections at a 2 month interval of either recombinant vaccinia virus expressing SIVMAC gp140 or wild type vaccinia virus (2 control animals) followed by 2 intramuscular boosts at months 5 and 8 of V2/HBsAg particles without adjuvant (one control animal received the V3/HBsAg particle and the other one received the native particle). Serum antibody responses were determined by ELISA and neutralization assay. Immunized macaques developed persistent antibodies against gp140 after the first injections but the V2/HBsAg boosts did not enhance this gp140 specific response. Despite having a low titer against V2 peptide, neutralizing antibodies were detected after the second V2/HBsAg boost. In light of these results, a third injection of the V2/HBsAg was given intradermally in the Syntex adjuvant formulation (SAF-1) before an intravenous cell free virus challenge with the molecular clone of the SIVMAC 251. Results of these protection experiments will be presented and discussed.

Keywords: Animal Antibodies, Viral/BIOSYNTHESIS/BLOOD Antibody Formation Hepatitis B Surface Antigens/IMMUNOLOGY HIV-1/IMMUNOLOGY Immunization Schedule Macaca mulatta Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL SIV/*IMMUNOLOGY Vaccines, Synthetic/*ADMINISTRATION & DOSAGE/IMMUNOLOGY Viral Envelope Proteins/IMMUNOLOGY Viral Vaccines/*ADMINISTRATION & DOSAGE/IMMUNOLOGY ABSTRACT
940730
M9470859

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .